Indeed, dual treatment with glaucarubin and BCL-2 inhibitor ABT-199 resulted in the killing of almost all of the MCPyV-positive MCC cells tested (Figure 6A). This evidence concerns the gene BCL2 and Merkel cell skin cancer.